

Asterand plc AGM Statement 9 May, 2007

At today's Annual General Meeting of Asterand plc ("Asterand" the "Company") Martyn Coombs, CEO, Asterand made the following statements relating to current trading.

"2006 marks the first full year of operations following the merger of Asterand, Inc. and Pharmagene plc to form Asterand plc. In this short time, there has been considerable progress toward the Company's goal of becoming profitable while enabling pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic through the provision of human tissue based services.

Total revenue in 2006 was £7.4 million compared to 2005 Proforma revenue of £5.5 million, a 35% increase, while operating expenses were reduced 46% from £11.9 million Proforma 2005 to £6.4 million in 2006.

Based on unaudited results, this trend is continuing in 2007. First quarter revenues were £1.7 million compared to £1.4 million in 2006, a 21% increase and first quarter operating expenses were reduced by approximately 25% compared to the same period in 2006. The Company had cash resources of £4.4 million at 30 April 2007.

The Company is selling a wider range of services to an expanded client base and is becoming the leading provider of human tissue and related services to the pharmaceutical sector".

At the Annual General Meeting and at the subsequent Extraordinary General Meeting of Asterand, each held today, all resolutions proposed at both meetings were duly passed.

A summary of the proxy voting at the Annual General Meeting and Extraordinary General Meeting will be published in the Investor Relations section of the Company's website at www.asterand.com.

Copies of the approved resolutions will be submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at:-

Financial Services Authority
25 The North Colonnade
Canary Wharf
London, E14 5HS

Tel: +44 (0) 20 7676 1000

ENDS